Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19
NCT04424901 · UConn Health · PHASE2 · terminated · last registry update 2023-04-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “reduction of Hospitalized COVID patients at UConnHealth” | – | Registry record, UConn Health |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC29A1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-11-07Also stopped (terminated): Clear Creek Bio, Inc., Brequinar Sodium + Dipyridamole 75 MG (NCT05166876)
- 2023-07-12Results posted on the registry: GE Healthcare, PET MPI + SPECT MPI (NCT03354273)
- 2023-02-06Results posted on the registry: Clear Creek Bio, Inc., Brequinar Sodium + Dipyridamole 75 MG (NCT05166876)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision